Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Express Scripts
Colorcon
Moodys
Harvard Business School

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR ZEPATIER


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Zepatier

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02743897 ↗ Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients Active, not recruiting Merck Sharp & Dohme Corp. Phase 1/Phase 2 2016-05-01 This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with the appropriate direct-acting antiviral (DAA) after the single kidney transplantation.
NCT02743897 ↗ Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients Active, not recruiting University of Pennsylvania Phase 1/Phase 2 2016-05-01 This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with the appropriate direct-acting antiviral (DAA) after the single kidney transplantation.
NCT02781649 ↗ Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Completed Merck Sharp & Dohme Corp. Phase 4 2016-07-20 In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant procedure and continued for 12 weeks post-renal transplant.
NCT02781649 ↗ Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Completed Johns Hopkins University Phase 4 2016-07-20 In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant procedure and continued for 12 weeks post-renal transplant.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zepatier

Condition Name

Condition Name for Zepatier
Intervention Trials
Hepatitis C 13
Hepatitis C, Chronic 3
Chronic Hepatitis C 2
Stage III Hepatocellular Carcinoma AJCC v7 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zepatier
Intervention Trials
Hepatitis C 24
Hepatitis 20
Hepatitis A 10
Hepatitis C, Chronic 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zepatier

Trials by Country

Trials by Country for Zepatier
Location Trials
United States 35
United Kingdom 3
Taiwan 3
Ireland 1
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zepatier
Location Trials
Pennsylvania 5
Massachusetts 4
Texas 3
Maryland 3
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zepatier

Clinical Trial Phase

Clinical Trial Phase for Zepatier
Clinical Trial Phase Trials
Phase 4 16
Phase 3 2
Phase 2 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zepatier
Clinical Trial Phase Trials
Completed 12
Terminated 4
Active, not recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zepatier

Sponsor Name

Sponsor Name for Zepatier
Sponsor Trials
Merck Sharp & Dohme Corp. 16
University of Pennsylvania 4
Massachusetts General Hospital 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zepatier
Sponsor Trials
Other 29
Industry 18
NIH 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKinsey
Express Scripts
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.